Jeremy Skillington
Directeur Général chez POOLBEG PHARMA PLC
Fortune : 152 364 $ au 31/05/2024
Relations actives
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Luke O'Neill | M | 60 | - | |
Cathal Friel | M | 59 | 4 ans | |
Brendan Buckley | M | 73 | 1 ans | |
Ian O'Connell | M | 37 | 3 ans | |
Eddie Gibson | M | 50 | 3 ans | |
Bernd Seizinger | M | 67 |
TriMod Therapeutics Ltd.
TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | 13 ans |
John G. Armstrong | M | - |
TriMod Therapeutics Ltd.
TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | - |
Ross Crockett | M | - | 3 ans | |
David Allmond | M | 54 | 1 ans | |
John McEvoy | M | 37 | - | |
Bruno Speder | M | - | 2 ans | |
Carol Dalton | F | - | 3 ans | |
Laura Maher | F | - | - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Nom | Sexe | Age | Sociétés liées | Collaboration |
---|---|---|---|---|
Patrick Ashe | M | 59 | - | |
Kingston H. G. Mills | M | - |
TriMod Therapeutics Ltd.
TriMod Therapeutics Ltd. BiotechnologyHealth Technology TriMod Therapeutics Ltd develops novel platform technologies to treat cancer and autoimmune diseases. It offers TriMoVac technology that enhances the patients' immune response to the tumour and promotes its eradication by attenuating its' immune subversion strategies. The company was founded by Kingston Mills and Jeremy Skillingtonand in 2011 is headquartered in Dublin, Ireland. | - |
David Hurley | M | - |
Opsona Therapeutics Ltd.
Opsona Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Opsona Therapeutics Ltd. operates as a immunology drug development company. It focuses on novel therapeutics and specializes in the prevention and treatment of solid organ transplantation, cancer, diabetes, autoimmune, inflammatory and Alzheimer’s diseases. The firm developed OPN-305, an antibody to reduce pro-inflammatory cytokine production, which is now at the clinical testing phase. The company was founded by Luke O'Neill, Kingston Mills and Dermot Kelleher in 2004 and is headquartered Dublin, Ireland. | - |
Salim Hamir | M | - | - | |
David English | M | - | 1 ans |
Statistiques
Pays | Relations | % du total |
---|---|---|
Royaume-Uni | 14 | 77,78% |
Irlande | 4 | 22,22% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Jeremy Skillington
- Réseau Personnel